|
|
|
Insider
Information: |
Baker Felix |
Relationship: |
Director, 10% Owner |
City: |
|
State: |
|
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
20 |
|
Direct
Shares |
927,207 |
|
Indirect Shares
|
141,861,898 |
|
|
Direct
Value |
$82,119,756 |
|
|
Indirect Value
|
$12,961,771,173 |
|
|
Total
Shares |
142,789,105 |
|
|
Total
Value |
$13,043,890,929 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
36
|
6
|
Stock
price went up :
|
15
|
6
|
Stock
price went down : |
21
|
0
|
|
|
|
Gain/Loss Ratio : |
0.0
|
6.0
|
Percentage
Gain/Loss : |
-24.3%
|
18.0%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Incyte Corp |
INCY |
Director, 10% Owner |
2023-09-29 |
559,963 |
2023-09-29 |
33,480,292 |
Premium* |
|
Ardea Biosciences Inc |
RDEA |
Director, 10% Owner |
2003-10-06 |
0 |
2012-02-01 |
116,454 |
Premium* |
|
Seagen Inc |
SGEN |
Director, 10% Owner |
2018-02-01 |
215,015 |
2018-02-01 |
44,355,335 |
Premium* |
|
Synageva BioPharma Corp |
GEVA |
Director, 10% Owner |
2015-06-22 |
100,503 |
2015-06-22 |
9,328,233 |
Premium* |
|
Viropharma Inc |
VPHM |
10% Owner |
2005-01-31 |
0 |
2011-12-14 |
303,264 |
Premium* |
|
Aceragen, Inc |
ACGN |
Director |
|
0 |
2017-07-03 |
145,453 |
Premium* |
|
Tapestry Pharmaceuticals Inc |
TPPHQ |
10% Owner |
|
0 |
2008-10-15 |
0 |
Premium* |
|
Genomic Health Inc |
GHDX |
Director, 10% Owner |
2012-10-01 |
288 |
2012-10-01 |
11,377,485 |
Premium* |
|
Allos Therapeutics Inc |
ALTH |
10% Owner |
|
0 |
2009-02-06 |
1,629 |
Premium* |
|
Biocryst Pharmaceuticals Inc |
BCRX |
10% Owner |
2016-08-16 |
46,918 |
2016-08-16 |
9,418,390 |
Premium* |
|
Heron Therapeutics Inc |
HRTX |
10% Owner |
|
0 |
2011-06-30 |
5,266,568 |
Premium* |
|
Adolor Corp |
ADLR |
10% Owner |
2010-04-26 |
0 |
2011-12-19 |
0 |
Premium* |
|
Diadexus Inc |
DDXS |
10% Owner |
|
0 |
2010-07-28 |
140,525 |
Premium* |
|
Pharmacyclics Inc |
PCYC |
10% Owner |
|
0 |
2011-08-22 |
1,809 |
Premium* |
|
Ocera Therapeutics Inc |
OCRX |
10% Owner |
2012-03-12 |
0 |
2012-03-14 |
57,704 |
Premium* |
|
XOMA Corporation |
XOMA |
Director, 10% Owner |
2012-10-29 |
0 |
2012-10-29 |
480,639 |
Premium* |
|
Neurogene |
NGNE |
10% Owner |
2015-08-07 |
4,520 |
|
0 |
Premium* |
|
Invitae Corp |
NVTA |
10% Owner |
|
0 |
2015-08-27 |
6,554,967 |
Premium* |
|
Bellicum Pharmaceuticals, Inc |
BLCM |
10% Owner |
|
0 |
2015-12-24 |
4,865,647 |
Premium* |
|
Kodiak Sciences Inc. |
KOD |
Director, 10% Owner |
2022-01-21 |
0 |
2022-06-06 |
15,967,504 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
1397 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 35 of 56
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
INCY |
Incyte Corp |
Director |
|
2010-09-23 |
4 |
S |
$14.86 |
$2,669,654 |
I/I |
(179,644) |
7,511,046 |
0 |
- |
|
INCY |
Incyte Corp |
Director |
|
2010-09-23 |
4 |
S |
$14.86 |
$85,033 |
I/I |
(5,722) |
239,258 |
0 |
- |
|
INCY |
Incyte Corp |
Director |
|
2010-09-23 |
4 |
S |
$14.86 |
$56,768 |
I/I |
(3,820) |
159,739 |
0 |
- |
|
INCY |
Incyte Corp |
Director |
|
2011-06-30 |
4 |
A |
$0.00 |
$0 |
I/I |
11,664 |
7,522,710 |
0 |
- |
|
INCY |
Incyte Corp |
Director |
|
2011-06-30 |
4 |
D |
$0.00 |
$0 |
I/I |
(11,664) |
227,594 |
0 |
- |
|
INCY |
Incyte Corp |
Director |
|
2011-11-29 |
4 |
B |
$12.19 |
$352,819 |
I/I |
28,890 |
266,387 |
2.25 |
- |
|
INCY |
Incyte Corp |
Director |
|
2011-12-01 |
4 |
B |
$13.78 |
$315,958 |
I/I |
22,380 |
288,767 |
2.25 |
- |
|
INCY |
Incyte Corp |
Director |
|
2011-12-05 |
4 |
B |
$13.88 |
$398,315 |
I/I |
28,685 |
317,452 |
2.25 |
- |
|
INCY |
Incyte Corp |
Director |
|
2011-12-05 |
4 |
B |
$13.88 |
$14,883,177 |
I/I |
1,071,825 |
11,000,714 |
2.25 |
- |
|
INCY |
Incyte Corp |
Director |
|
2011-12-06 |
4 |
B |
$13.52 |
$122,526 |
I/I |
9,057 |
326,509 |
2.25 |
- |
|
INCY |
Incyte Corp |
Director |
|
2011-12-06 |
4 |
B |
$13.52 |
$4,578,060 |
I/I |
338,406 |
11,339,120 |
2.25 |
- |
|
INCY |
Incyte Corp |
Director |
|
2011-12-07 |
4 |
B |
$13.21 |
$1,915,214 |
I/I |
144,903 |
11,484,023 |
2.25 |
- |
|
INCY |
Incyte Corp |
Director |
|
2011-12-07 |
4 |
B |
$13.21 |
$51,256 |
I/I |
3,878 |
330,387 |
2.25 |
- |
|
INCY |
Incyte Corp |
Director |
|
2011-12-08 |
4 |
B |
$13.44 |
$2,992,186 |
I/I |
222,320 |
11,706,343 |
2.25 |
- |
|
INCY |
Incyte Corp |
Director |
|
2011-12-08 |
4 |
B |
$13.44 |
$80,282 |
I/I |
5,965 |
336,352 |
2.25 |
- |
|
INCY |
Incyte Corp |
Director |
|
2011-12-09 |
4 |
B |
$13.19 |
$64,462 |
I/I |
4,862 |
341,214 |
2.25 |
- |
|
INCY |
Incyte Corp |
Director |
|
2011-12-09 |
4 |
B |
$13.19 |
$2,402,409 |
I/I |
181,201 |
11,887,544 |
2.25 |
- |
|
INCY |
Incyte Corp |
Director |
|
2012-01-12 |
4 |
B |
$16.21 |
$5,297,473 |
I/I |
325,728 |
12,213,272 |
2.25 |
- |
|
INCY |
Incyte Corp |
Director |
|
2012-01-12 |
4 |
B |
$16.21 |
$142,615 |
I/I |
8,769 |
349,983 |
2.25 |
- |
|
INCY |
Incyte Corp |
Director |
|
2012-01-13 |
4 |
B |
$16.46 |
$96,794 |
I/I |
5,856 |
355,839 |
2.25 |
- |
|
INCY |
Incyte Corp |
Director |
|
2012-01-13 |
4 |
B |
$16.46 |
$3,595,234 |
I/I |
217,511 |
12,430,783 |
2.25 |
- |
|
INCY |
Incyte Corp |
Director |
|
2022-02-10 |
4 |
B |
$66.57 |
$55,276,314 |
I/I |
819,015 |
31,752,130 |
2.25 |
% |
|
INCY |
Incyte Corp |
Director |
|
2022-02-11 |
4 |
B |
$66.81 |
$18,475,727 |
I/I |
276,507 |
32,028,637 |
2.25 |
% |
|
INCY |
Incyte Corp |
Director |
|
2022-02-14 |
4 |
B |
$66.02 |
$33,200,362 |
I/I |
502,852 |
32,531,489 |
2.25 |
% |
|
INCY |
Incyte Corp |
Director |
|
2022-02-17 |
4 |
B |
$67.40 |
$19,844,805 |
I/I |
292,972 |
32,824,461 |
2.25 |
% |
|
1397 Records found
|
|
Page 35 of 56 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|